ERBB2 and breast carcinoma: Taken together, these findings suggested that an inhibitory effect of ANT2 shRNA on the PI3K/Akt signaling pathway in HER2/neu-overexpressing breast cancer cells (SK-BR3) might be mediated by degradation of HER2/neu protein rather than Akt down-regulation, especially in the early time of transfection.